Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced its intention to offer and sell 10,000,000 shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. As part of this offering, Ocata Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock.

Jefferies LLC, Cowen and Company, LLC and Piper Jaffray & Co. are acting as joint book-runners for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-199311), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on November 14, 2014. All of the shares in the proposed offering are to be sold by Ocata Therapeutics. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by contacting Jefferies LLC, 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Prospectus Department, or by email to prospectus_department@jefferies.com; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (631) 274-2806, or by fax at (631) 254-7140; or Piper Jaffray & Co. at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email to prospectus@pjc.com.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel therapies based on terminally differentiated cells.